Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: KPd in Relapsed/Refractory Multiple Myeloma
NCT04191616Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2020
- Primary completion
- Nov 2022
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Primary endpoint: Overall Response Rate up to 42 weeks. Started Aug 2020; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04191616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191616.